EMA Withdrawn: Sebivo (telbivudine) — Novartis Europharm Limited

View source ↗

Summary

Withdrawal of Sebivo (telbivudine) from the market by Novartis Europharm Limited for chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Sebivo (telbivudine)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis B, Chronic. MAH: Novartis Europharm Limited. Decision date: 12/04/2018